nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—UGT1A1—Mycophenolic acid—systemic scleroderma	0.124	0.192	CbGbCtD
Erlotinib—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0693	0.107	CbGbCtD
Erlotinib—ABCG2—Leflunomide—systemic scleroderma	0.0617	0.0954	CbGbCtD
Erlotinib—CYP2C8—Mometasone—systemic scleroderma	0.051	0.0789	CbGbCtD
Erlotinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0381	0.059	CbGbCtD
Erlotinib—ALB—Captopril—systemic scleroderma	0.0334	0.0516	CbGbCtD
Erlotinib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0267	0.0412	CbGbCtD
Erlotinib—ALB—Mycophenolate mofetil—systemic scleroderma	0.0263	0.0406	CbGbCtD
Erlotinib—CYP1A2—Leflunomide—systemic scleroderma	0.0254	0.0393	CbGbCtD
Erlotinib—ABCB1—Lisinopril—systemic scleroderma	0.0233	0.0361	CbGbCtD
Erlotinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0211	0.0327	CbGbCtD
Erlotinib—ALB—Prednisone—systemic scleroderma	0.021	0.0325	CbGbCtD
Erlotinib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0203	0.0314	CbGbCtD
Erlotinib—ABCB1—Captopril—systemic scleroderma	0.0175	0.027	CbGbCtD
Erlotinib—CYP2D6—Captopril—systemic scleroderma	0.0164	0.0254	CbGbCtD
Erlotinib—ABCG2—Methotrexate—systemic scleroderma	0.0153	0.0236	CbGbCtD
Erlotinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0137	0.0213	CbGbCtD
Erlotinib—ABCB1—Prednisone—systemic scleroderma	0.011	0.017	CbGbCtD
Erlotinib—ALB—Methotrexate—systemic scleroderma	0.0105	0.0163	CbGbCtD
Erlotinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00823	0.0127	CbGbCtD
Erlotinib—CYP3A4—Prednisone—systemic scleroderma	0.00658	0.0102	CbGbCtD
Erlotinib—ABCB1—Methotrexate—systemic scleroderma	0.00551	0.00853	CbGbCtD
Erlotinib—Vandetanib—BLK—systemic scleroderma	0.00478	1	CrCbGaD
Erlotinib—JAK3—connective tissue—systemic scleroderma	0.00237	0.0474	CbGeAlD
Erlotinib—NR1I2—digestive system—systemic scleroderma	0.00214	0.0428	CbGeAlD
Erlotinib—FLT3—connective tissue—systemic scleroderma	0.00187	0.0374	CbGeAlD
Erlotinib—LTK—lung—systemic scleroderma	0.00179	0.0358	CbGeAlD
Erlotinib—AURKC—tendon—systemic scleroderma	0.00176	0.0352	CbGeAlD
Erlotinib—JAK3—digestive system—systemic scleroderma	0.00171	0.0342	CbGeAlD
Erlotinib—TNK1—tendon—systemic scleroderma	0.0015	0.0299	CbGeAlD
Erlotinib—JAK3—lung—systemic scleroderma	0.00143	0.0286	CbGeAlD
Erlotinib—TNK1—lung—systemic scleroderma	0.00131	0.0263	CbGeAlD
Erlotinib—MAP3K19—lung—systemic scleroderma	0.0013	0.026	CbGeAlD
Erlotinib—ABL2—tendon—systemic scleroderma	0.00123	0.0245	CbGeAlD
Erlotinib—ULK3—digestive system—systemic scleroderma	0.00117	0.0233	CbGeAlD
Erlotinib—PIP4K2C—tendon—systemic scleroderma	0.00116	0.0232	CbGeAlD
Erlotinib—FLT3—lung—systemic scleroderma	0.00113	0.0226	CbGeAlD
Erlotinib—ULK3—tendon—systemic scleroderma	0.00111	0.0222	CbGeAlD
Erlotinib—MKNK1—digestive system—systemic scleroderma	0.0011	0.0219	CbGeAlD
Erlotinib—ABL2—lung—systemic scleroderma	0.00108	0.0215	CbGeAlD
Erlotinib—EGFR—lung—systemic scleroderma	0.00105	0.021	CbGeAlD
Erlotinib—PIP4K2C—lung—systemic scleroderma	0.00102	0.0204	CbGeAlD
Erlotinib—SLK—tendon—systemic scleroderma	0.000988	0.0198	CbGeAlD
Erlotinib—ULK3—lung—systemic scleroderma	0.000973	0.0195	CbGeAlD
Erlotinib—MKNK1—lung—systemic scleroderma	0.000916	0.0183	CbGeAlD
Erlotinib—STK10—digestive system—systemic scleroderma	0.000903	0.0181	CbGeAlD
Erlotinib—SLK—lung—systemic scleroderma	0.000867	0.0173	CbGeAlD
Erlotinib—ABL1—connective tissue—systemic scleroderma	0.000861	0.0172	CbGeAlD
Erlotinib—STK10—tendon—systemic scleroderma	0.000859	0.0172	CbGeAlD
Erlotinib—UGT1A1—digestive system—systemic scleroderma	0.000853	0.0171	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—systemic scleroderma	0.000788	0.0158	CbGeAlD
Erlotinib—ABL1—skin of body—systemic scleroderma	0.000778	0.0156	CbGeAlD
Erlotinib—MAP2K5—tendon—systemic scleroderma	0.000768	0.0153	CbGeAlD
Erlotinib—STK10—lung—systemic scleroderma	0.000754	0.0151	CbGeAlD
Erlotinib—CYP1B1—connective tissue—systemic scleroderma	0.00073	0.0146	CbGeAlD
Erlotinib—MAP2K5—lung—systemic scleroderma	0.000674	0.0135	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—systemic scleroderma	0.000667	0.0133	CbGeAlD
Erlotinib—CYP1B1—skin of body—systemic scleroderma	0.000659	0.0132	CbGeAlD
Erlotinib—SLCO2B1—digestive system—systemic scleroderma	0.000628	0.0125	CbGeAlD
Erlotinib—ABL1—digestive system—systemic scleroderma	0.000622	0.0124	CbGeAlD
Erlotinib—SLCO2B1—tendon—systemic scleroderma	0.000597	0.0119	CbGeAlD
Erlotinib—ABL1—tendon—systemic scleroderma	0.000592	0.0118	CbGeAlD
Erlotinib—ORM1—lung—systemic scleroderma	0.000547	0.0109	CbGeAlD
Erlotinib—CYP1B1—digestive system—systemic scleroderma	0.000527	0.0105	CbGeAlD
Erlotinib—SLCO2B1—lung—systemic scleroderma	0.000524	0.0105	CbGeAlD
Erlotinib—ABCB1—blood vessel—systemic scleroderma	0.000522	0.0104	CbGeAlD
Erlotinib—ABL1—lung—systemic scleroderma	0.00052	0.0104	CbGeAlD
Erlotinib—CYP1B1—tendon—systemic scleroderma	0.000501	0.01	CbGeAlD
Erlotinib—CYP1A1—skin of body—systemic scleroderma	0.000466	0.00931	CbGeAlD
Erlotinib—CYP1B1—lung—systemic scleroderma	0.00044	0.0088	CbGeAlD
Erlotinib—CYP1A2—digestive system—systemic scleroderma	0.000378	0.00755	CbGeAlD
Erlotinib—CYP1A1—digestive system—systemic scleroderma	0.000372	0.00745	CbGeAlD
Erlotinib—CYP3A5—digestive system—systemic scleroderma	0.000364	0.00728	CbGeAlD
Erlotinib—ABCG2—lung—systemic scleroderma	0.000328	0.00655	CbGeAlD
Erlotinib—CYP1A2—lung—systemic scleroderma	0.000315	0.00631	CbGeAlD
Erlotinib—CYP1A1—lung—systemic scleroderma	0.000311	0.00622	CbGeAlD
Erlotinib—CYP3A5—lung—systemic scleroderma	0.000304	0.00608	CbGeAlD
Erlotinib—CYP3A4—digestive system—systemic scleroderma	0.000273	0.00547	CbGeAlD
Erlotinib—CYP2D6—digestive system—systemic scleroderma	0.000269	0.00538	CbGeAlD
Erlotinib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000223	0.00096	CcSEcCtD
Erlotinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000222	0.000959	CcSEcCtD
Erlotinib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000222	0.000958	CcSEcCtD
Erlotinib—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000952	CcSEcCtD
Erlotinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00022	0.00095	CcSEcCtD
Erlotinib—Loss of consciousness—Lisinopril—systemic scleroderma	0.00022	0.000949	CcSEcCtD
Erlotinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000946	CcSEcCtD
Erlotinib—Cough—Lisinopril—systemic scleroderma	0.000218	0.000942	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000218	0.000939	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000217	0.000937	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000217	0.000934	CcSEcCtD
Erlotinib—Anorexia—Mycophenolic acid—systemic scleroderma	0.000216	0.000932	CcSEcCtD
Erlotinib—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000932	CcSEcCtD
Erlotinib—Insomnia—Leflunomide—systemic scleroderma	0.000215	0.000927	CcSEcCtD
Erlotinib—Myalgia—Lisinopril—systemic scleroderma	0.000213	0.000919	CcSEcCtD
Erlotinib—Arthralgia—Lisinopril—systemic scleroderma	0.000213	0.000919	CcSEcCtD
Erlotinib—Chest pain—Lisinopril—systemic scleroderma	0.000213	0.000919	CcSEcCtD
Erlotinib—Anxiety—Lisinopril—systemic scleroderma	0.000212	0.000916	CcSEcCtD
Erlotinib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000915	CcSEcCtD
Erlotinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000212	0.000914	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000212	0.000913	CcSEcCtD
Erlotinib—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00021	0.000908	CcSEcCtD
Erlotinib—Dyspepsia—Leflunomide—systemic scleroderma	0.000209	0.000902	CcSEcCtD
Erlotinib—Pancreatitis—Prednisone—systemic scleroderma	0.000209	0.000902	CcSEcCtD
Erlotinib—Vomiting—Mometasone—systemic scleroderma	0.000209	0.0009	CcSEcCtD
Erlotinib—Rash—Mometasone—systemic scleroderma	0.000207	0.000893	CcSEcCtD
Erlotinib—Asthenia—Captopril—systemic scleroderma	0.000207	0.000892	CcSEcCtD
Erlotinib—Dermatitis—Mometasone—systemic scleroderma	0.000207	0.000892	CcSEcCtD
Erlotinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000207	0.000891	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000207	0.000891	CcSEcCtD
Erlotinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000206	0.000888	CcSEcCtD
Erlotinib—Headache—Mometasone—systemic scleroderma	0.000206	0.000887	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000205	0.000885	CcSEcCtD
Erlotinib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000205	0.000885	CcSEcCtD
Erlotinib—Fatigue—Leflunomide—systemic scleroderma	0.000205	0.000884	CcSEcCtD
Erlotinib—Oedema—Lisinopril—systemic scleroderma	0.000204	0.000881	CcSEcCtD
Erlotinib—Pruritus—Captopril—systemic scleroderma	0.000204	0.00088	CcSEcCtD
Erlotinib—Constipation—Leflunomide—systemic scleroderma	0.000203	0.000877	CcSEcCtD
Erlotinib—Pain—Leflunomide—systemic scleroderma	0.000203	0.000877	CcSEcCtD
Erlotinib—Infection—Lisinopril—systemic scleroderma	0.000203	0.000875	CcSEcCtD
Erlotinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000202	0.000872	CcSEcCtD
Erlotinib—Shock—Lisinopril—systemic scleroderma	0.000201	0.000867	CcSEcCtD
Erlotinib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.0002	0.000862	CcSEcCtD
Erlotinib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.0002	0.000861	CcSEcCtD
Erlotinib—Neutropenia—Prednisone—systemic scleroderma	0.000199	0.00086	CcSEcCtD
Erlotinib—Abdominal pain—Azathioprine—systemic scleroderma	0.000199	0.000858	CcSEcCtD
Erlotinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000199	0.000858	CcSEcCtD
Erlotinib—Skin disorder—Lisinopril—systemic scleroderma	0.000198	0.000856	CcSEcCtD
Erlotinib—Diarrhoea—Captopril—systemic scleroderma	0.000197	0.000851	CcSEcCtD
Erlotinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000197	0.00085	CcSEcCtD
Erlotinib—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000197	0.000848	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000196	0.000844	CcSEcCtD
Erlotinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000195	0.000843	CcSEcCtD
Erlotinib—Nausea—Mometasone—systemic scleroderma	0.000195	0.000841	CcSEcCtD
Erlotinib—Anorexia—Lisinopril—systemic scleroderma	0.000195	0.00084	CcSEcCtD
Erlotinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000194	0.000838	CcSEcCtD
Erlotinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000194	0.000836	CcSEcCtD
Erlotinib—Pain—Mycophenolic acid—systemic scleroderma	0.000194	0.000836	CcSEcCtD
Erlotinib—ABCB1—digestive system—systemic scleroderma	0.000193	0.00387	CbGeAlD
Erlotinib—Weight decreased—Prednisone—systemic scleroderma	0.000193	0.000832	CcSEcCtD
Erlotinib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000831	CcSEcCtD
Erlotinib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000825	CcSEcCtD
Erlotinib—Dizziness—Captopril—systemic scleroderma	0.000191	0.000823	CcSEcCtD
Erlotinib—Depression—Prednisone—systemic scleroderma	0.00019	0.000818	CcSEcCtD
Erlotinib—Abdominal pain—Leflunomide—systemic scleroderma	0.000188	0.00081	CcSEcCtD
Erlotinib—Body temperature increased—Leflunomide—systemic scleroderma	0.000188	0.00081	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000187	0.000809	CcSEcCtD
Erlotinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000805	CcSEcCtD
Erlotinib—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000805	CcSEcCtD
Erlotinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000805	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisone—systemic scleroderma	0.000186	0.000804	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000186	0.000804	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000186	0.000803	CcSEcCtD
Erlotinib—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000802	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000186	0.000801	CcSEcCtD
Erlotinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000185	0.0008	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000185	0.0008	CcSEcCtD
Erlotinib—Insomnia—Lisinopril—systemic scleroderma	0.000185	0.000797	CcSEcCtD
Erlotinib—Vomiting—Captopril—systemic scleroderma	0.000183	0.000791	CcSEcCtD
Erlotinib—Dyspnoea—Lisinopril—systemic scleroderma	0.000182	0.000785	CcSEcCtD
Erlotinib—Rash—Captopril—systemic scleroderma	0.000182	0.000784	CcSEcCtD
Erlotinib—Dermatitis—Captopril—systemic scleroderma	0.000182	0.000784	CcSEcCtD
Erlotinib—Headache—Captopril—systemic scleroderma	0.000181	0.000779	CcSEcCtD
Erlotinib—Dyspepsia—Lisinopril—systemic scleroderma	0.00018	0.000775	CcSEcCtD
Erlotinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000179	0.000773	CcSEcCtD
Erlotinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000179	0.000773	CcSEcCtD
Erlotinib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000772	CcSEcCtD
Erlotinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000767	CcSEcCtD
Erlotinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000178	0.000766	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000176	0.00076	CcSEcCtD
Erlotinib—Fatigue—Lisinopril—systemic scleroderma	0.000176	0.000759	CcSEcCtD
Erlotinib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000759	CcSEcCtD
Erlotinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000757	CcSEcCtD
Erlotinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000756	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—systemic scleroderma	0.000175	0.000754	CcSEcCtD
Erlotinib—Pain—Lisinopril—systemic scleroderma	0.000175	0.000753	CcSEcCtD
Erlotinib—Constipation—Lisinopril—systemic scleroderma	0.000175	0.000753	CcSEcCtD
Erlotinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000174	0.00075	CcSEcCtD
Erlotinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000172	0.000743	CcSEcCtD
Erlotinib—Haemoglobin—Prednisone—systemic scleroderma	0.000172	0.00074	CcSEcCtD
Erlotinib—Nausea—Captopril—systemic scleroderma	0.000171	0.000739	CcSEcCtD
Erlotinib—Haemorrhage—Prednisone—systemic scleroderma	0.000171	0.000736	CcSEcCtD
Erlotinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000736	CcSEcCtD
Erlotinib—Asthenia—Leflunomide—systemic scleroderma	0.000171	0.000736	CcSEcCtD
Erlotinib—Pruritus—Leflunomide—systemic scleroderma	0.000168	0.000725	CcSEcCtD
Erlotinib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000168	0.000724	CcSEcCtD
Erlotinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000167	0.00072	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—systemic scleroderma	0.000167	0.000719	CcSEcCtD
Erlotinib—Dizziness—Azathioprine—systemic scleroderma	0.000166	0.000718	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000703	CcSEcCtD
Erlotinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000163	0.000702	CcSEcCtD
Erlotinib—Diarrhoea—Leflunomide—systemic scleroderma	0.000163	0.000701	CcSEcCtD
Erlotinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000698	CcSEcCtD
Erlotinib—ABCB1—lung—systemic scleroderma	0.000162	0.00323	CbGeAlD
Erlotinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000161	0.000696	CcSEcCtD
Erlotinib—Abdominal pain—Lisinopril—systemic scleroderma	0.000161	0.000696	CcSEcCtD
Erlotinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.00016	0.000692	CcSEcCtD
Erlotinib—Vomiting—Azathioprine—systemic scleroderma	0.00016	0.00069	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—systemic scleroderma	0.00016	0.00069	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—systemic scleroderma	0.00016	0.000688	CcSEcCtD
Erlotinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000688	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—systemic scleroderma	0.000159	0.000686	CcSEcCtD
Erlotinib—Infestation—Methotrexate—systemic scleroderma	0.000159	0.000686	CcSEcCtD
Erlotinib—Rash—Azathioprine—systemic scleroderma	0.000159	0.000684	CcSEcCtD
Erlotinib—Dermatitis—Azathioprine—systemic scleroderma	0.000159	0.000684	CcSEcCtD
Erlotinib—Depression—Methotrexate—systemic scleroderma	0.000158	0.000684	CcSEcCtD
Erlotinib—Headache—Azathioprine—systemic scleroderma	0.000158	0.00068	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000158	0.00068	CcSEcCtD
Erlotinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000679	CcSEcCtD
Erlotinib—Dizziness—Leflunomide—systemic scleroderma	0.000157	0.000678	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—systemic scleroderma	0.000156	0.000674	CcSEcCtD
Erlotinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000671	CcSEcCtD
Erlotinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000155	0.000669	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—systemic scleroderma	0.000155	0.000668	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—systemic scleroderma	0.000154	0.000666	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000666	CcSEcCtD
Erlotinib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000153	0.00066	CcSEcCtD
Erlotinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000153	0.00066	CcSEcCtD
Erlotinib—Arrhythmia—Prednisone—systemic scleroderma	0.000153	0.000658	CcSEcCtD
Erlotinib—Vomiting—Leflunomide—systemic scleroderma	0.000151	0.000652	CcSEcCtD
Erlotinib—Alopecia—Prednisone—systemic scleroderma	0.000151	0.000651	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00015	0.000648	CcSEcCtD
Erlotinib—Dizziness—Mycophenolic acid—systemic scleroderma	0.00015	0.000647	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—systemic scleroderma	0.00015	0.000647	CcSEcCtD
Erlotinib—Rash—Leflunomide—systemic scleroderma	0.00015	0.000646	CcSEcCtD
Erlotinib—Dermatitis—Leflunomide—systemic scleroderma	0.00015	0.000646	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—systemic scleroderma	0.00015	0.000645	CcSEcCtD
Erlotinib—Nausea—Azathioprine—systemic scleroderma	0.000149	0.000645	CcSEcCtD
Erlotinib—Headache—Leflunomide—systemic scleroderma	0.000149	0.000642	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—systemic scleroderma	0.000149	0.000641	CcSEcCtD
Erlotinib—Erythema—Prednisone—systemic scleroderma	0.000149	0.000641	CcSEcCtD
Erlotinib—Asthenia—Lisinopril—systemic scleroderma	0.000147	0.000632	CcSEcCtD
Erlotinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000631	CcSEcCtD
Erlotinib—Pruritus—Lisinopril—systemic scleroderma	0.000144	0.000623	CcSEcCtD
Erlotinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000144	0.000622	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—systemic scleroderma	0.000143	0.000619	CcSEcCtD
Erlotinib—Rash—Mycophenolic acid—systemic scleroderma	0.000143	0.000617	CcSEcCtD
Erlotinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000143	0.000616	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—systemic scleroderma	0.000143	0.000615	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—systemic scleroderma	0.000143	0.000615	CcSEcCtD
Erlotinib—Headache—Mycophenolic acid—systemic scleroderma	0.000142	0.000613	CcSEcCtD
Erlotinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00061	CcSEcCtD
Erlotinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00061	CcSEcCtD
Erlotinib—Nausea—Leflunomide—systemic scleroderma	0.000141	0.000609	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000141	0.000608	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—systemic scleroderma	0.00014	0.000603	CcSEcCtD
Erlotinib—Diarrhoea—Lisinopril—systemic scleroderma	0.00014	0.000603	CcSEcCtD
Erlotinib—Dizziness—Lisinopril—systemic scleroderma	0.000135	0.000583	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—systemic scleroderma	0.000135	0.000582	CcSEcCtD
Erlotinib—Nausea—Mycophenolic acid—systemic scleroderma	0.000135	0.000581	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—systemic scleroderma	0.000133	0.000575	CcSEcCtD
Erlotinib—Syncope—Prednisone—systemic scleroderma	0.000133	0.000575	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—systemic scleroderma	0.000131	0.000563	CcSEcCtD
Erlotinib—Vomiting—Lisinopril—systemic scleroderma	0.00013	0.00056	CcSEcCtD
Erlotinib—Rash—Lisinopril—systemic scleroderma	0.000129	0.000555	CcSEcCtD
Erlotinib—Dermatitis—Lisinopril—systemic scleroderma	0.000129	0.000555	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000129	0.000555	CcSEcCtD
Erlotinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000554	CcSEcCtD
Erlotinib—Chills—Methotrexate—systemic scleroderma	0.000128	0.000552	CcSEcCtD
Erlotinib—Headache—Lisinopril—systemic scleroderma	0.000128	0.000552	CcSEcCtD
Erlotinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000546	CcSEcCtD
Erlotinib—Myalgia—Prednisone—systemic scleroderma	0.000127	0.000546	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—systemic scleroderma	0.000127	0.000546	CcSEcCtD
Erlotinib—Anxiety—Prednisone—systemic scleroderma	0.000126	0.000544	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—systemic scleroderma	0.000126	0.000544	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000126	0.000542	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—systemic scleroderma	0.000125	0.000539	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—systemic scleroderma	0.000124	0.000536	CcSEcCtD
Erlotinib—Erythema—Methotrexate—systemic scleroderma	0.000124	0.000536	CcSEcCtD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000123	0.00184	CbGpPWpGaD
Erlotinib—EGFR—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000122	0.00183	CbGpPWpGaD
Erlotinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000528	CcSEcCtD
Erlotinib—ABL2—Axon guidance—MMP2—systemic scleroderma	0.000121	0.00181	CbGpPWpGaD
Erlotinib—Nausea—Lisinopril—systemic scleroderma	0.000121	0.000523	CcSEcCtD
Erlotinib—Oedema—Prednisone—systemic scleroderma	0.000121	0.000523	CcSEcCtD
Erlotinib—Infection—Prednisone—systemic scleroderma	0.00012	0.00052	CcSEcCtD
Erlotinib—Back pain—Methotrexate—systemic scleroderma	0.00012	0.000518	CcSEcCtD
Erlotinib—Shock—Prednisone—systemic scleroderma	0.000119	0.000515	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000119	0.000513	CcSEcCtD
Erlotinib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000119	0.00178	CbGpPWpGaD
Erlotinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000118	0.00051	CcSEcCtD
Erlotinib—CYP1A1—PPARA activates gene expression—CTGF—systemic scleroderma	0.000118	0.00176	CbGpPWpGaD
Erlotinib—Skin disorder—Prednisone—systemic scleroderma	0.000118	0.000508	CcSEcCtD
Erlotinib—MKNK1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000116	0.00174	CbGpPWpGaD
Erlotinib—EGFR—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.000116	0.00174	CbGpPWpGaD
Erlotinib—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000116	0.00173	CbGpPWpGaD
Erlotinib—Anorexia—Prednisone—systemic scleroderma	0.000116	0.000499	CcSEcCtD
Erlotinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000491	CcSEcCtD
Erlotinib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000487	CcSEcCtD
Erlotinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000486	CcSEcCtD
Erlotinib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000484	CcSEcCtD
Erlotinib—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000112	0.00167	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—RHOB—systemic scleroderma	0.000111	0.00166	CbGpPWpGaD
Erlotinib—MAP2K5—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000111	0.00166	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000111	0.00166	CbGpPWpGaD
Erlotinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000111	0.000477	CcSEcCtD
Erlotinib—EGFR—Axon guidance—RHOB—systemic scleroderma	0.00011	0.00165	CbGpPWpGaD
Erlotinib—Insomnia—Prednisone—systemic scleroderma	0.00011	0.000473	CcSEcCtD
Erlotinib—Cough—Methotrexate—systemic scleroderma	0.000108	0.000467	CcSEcCtD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000108	0.00161	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HSPG2—systemic scleroderma	0.000107	0.00159	CbGpPWpGaD
Erlotinib—Dyspepsia—Prednisone—systemic scleroderma	0.000107	0.000461	CcSEcCtD
Erlotinib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000458	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—systemic scleroderma	0.000106	0.000456	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—systemic scleroderma	0.000106	0.000456	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—systemic scleroderma	0.000106	0.000456	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—systemic scleroderma	0.000105	0.000455	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000105	0.000453	CcSEcCtD
Erlotinib—Fatigue—Prednisone—systemic scleroderma	0.000105	0.000451	CcSEcCtD
Erlotinib—Constipation—Prednisone—systemic scleroderma	0.000104	0.000447	CcSEcCtD
Erlotinib—MKNK1—Disease—CSK—systemic scleroderma	0.000103	0.00154	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—SMAD7—systemic scleroderma	0.000103	0.00153	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—MMP2—systemic scleroderma	0.000102	0.00153	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000102	0.00152	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000101	0.00151	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—RHOB—systemic scleroderma	0.000101	0.00151	CbGpPWpGaD
Erlotinib—EGFR—LPA receptor mediated events—MMP9—systemic scleroderma	0.000101	0.0015	CbGpPWpGaD
Erlotinib—Infection—Methotrexate—systemic scleroderma	0.000101	0.000434	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—systemic scleroderma	9.94e-05	0.000429	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—systemic scleroderma	9.92e-05	0.000428	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—systemic scleroderma	9.92e-05	0.000428	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—systemic scleroderma	9.85e-05	0.000425	CcSEcCtD
Erlotinib—EGFR—AGE/RAGE pathway—MMP9—systemic scleroderma	9.83e-05	0.00147	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	9.73e-05	0.00145	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD247—systemic scleroderma	9.7e-05	0.00145	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—SELP—systemic scleroderma	9.67e-05	0.00144	CbGpPWpGaD
Erlotinib—Anorexia—Methotrexate—systemic scleroderma	9.66e-05	0.000417	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—systemic scleroderma	9.59e-05	0.000414	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—systemic scleroderma	9.59e-05	0.000414	CcSEcCtD
Erlotinib—EGFR—MAPK Signaling Pathway—IL1A—systemic scleroderma	9.46e-05	0.00141	CbGpPWpGaD
Erlotinib—ABL1—Regulation of Telomerase—TGFB1—systemic scleroderma	9.25e-05	0.00138	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	9.24e-05	0.00138	CbGpPWpGaD
Erlotinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.24e-05	0.000398	CcSEcCtD
Erlotinib—ABL1—Developmental Biology—RHOB—systemic scleroderma	9.21e-05	0.00137	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—IL1B—systemic scleroderma	9.2e-05	0.00137	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	9.2e-05	0.00137	CbGpPWpGaD
Erlotinib—Insomnia—Methotrexate—systemic scleroderma	9.17e-05	0.000395	CcSEcCtD
Erlotinib—ABL2—Axon guidance—MMP9—systemic scleroderma	9.12e-05	0.00136	CbGpPWpGaD
Erlotinib—Dyspnoea—Methotrexate—systemic scleroderma	9.04e-05	0.00039	CcSEcCtD
Erlotinib—ABL1—Hemostasis—RHOB—systemic scleroderma	9.03e-05	0.00135	CbGpPWpGaD
Erlotinib—Dyspepsia—Methotrexate—systemic scleroderma	8.92e-05	0.000385	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—systemic scleroderma	8.81e-05	0.00038	CcSEcCtD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	8.79e-05	0.00131	CbGpPWpGaD
Erlotinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.75e-05	0.000377	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—systemic scleroderma	8.74e-05	0.000377	CcSEcCtD
Erlotinib—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	8.73e-05	0.0013	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	8.71e-05	0.0013	CbGpPWpGaD
Erlotinib—Asthenia—Prednisone—systemic scleroderma	8.7e-05	0.000375	CcSEcCtD
Erlotinib—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	8.68e-05	0.0013	CbGpPWpGaD
Erlotinib—Pain—Methotrexate—systemic scleroderma	8.67e-05	0.000374	CcSEcCtD
Erlotinib—ABL2—Developmental Biology—MMP2—systemic scleroderma	8.66e-05	0.00129	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—CCL2—systemic scleroderma	8.63e-05	0.00129	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	8.62e-05	0.00129	CbGpPWpGaD
Erlotinib—Pruritus—Prednisone—systemic scleroderma	8.58e-05	0.00037	CcSEcCtD
Erlotinib—JAK3—Immune System—CSK—systemic scleroderma	8.42e-05	0.00126	CbGpPWpGaD
Erlotinib—Diarrhoea—Prednisone—systemic scleroderma	8.3e-05	0.000358	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.29e-05	0.000358	CcSEcCtD
Erlotinib—JAK3—Immune System—IRF5—systemic scleroderma	8.29e-05	0.00124	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—CSK—systemic scleroderma	8.23e-05	0.00123	CbGpPWpGaD
Erlotinib—Dizziness—Prednisone—systemic scleroderma	8.02e-05	0.000346	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—systemic scleroderma	8.01e-05	0.000346	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—systemic scleroderma	8.01e-05	0.000346	CcSEcCtD
Erlotinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	7.97e-05	0.00119	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—RHOB—systemic scleroderma	7.93e-05	0.00118	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD247—systemic scleroderma	7.92e-05	0.00118	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IRF8—systemic scleroderma	7.92e-05	0.00118	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ITGAM—systemic scleroderma	7.92e-05	0.00118	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—CCL2—systemic scleroderma	7.92e-05	0.00118	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Telomerase—TGFB1—systemic scleroderma	7.91e-05	0.00118	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—RHOB—systemic scleroderma	7.87e-05	0.00117	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	7.85e-05	0.00117	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	7.81e-05	0.00117	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—ITGAM—systemic scleroderma	7.73e-05	0.00115	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—CTGF—systemic scleroderma	7.73e-05	0.00115	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SMAD7—systemic scleroderma	7.73e-05	0.00115	CbGpPWpGaD
Erlotinib—Vomiting—Prednisone—systemic scleroderma	7.71e-05	0.000333	CcSEcCtD
Erlotinib—EPHA6—Axon guidance—MMP9—systemic scleroderma	7.69e-05	0.00115	CbGpPWpGaD
Erlotinib—Rash—Prednisone—systemic scleroderma	7.65e-05	0.00033	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—systemic scleroderma	7.64e-05	0.00033	CcSEcCtD
Erlotinib—Headache—Prednisone—systemic scleroderma	7.6e-05	0.000328	CcSEcCtD
Erlotinib—JAK3—Hemostasis—MMP1—systemic scleroderma	7.57e-05	0.00113	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	7.5e-05	0.00112	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HSPG2—systemic scleroderma	7.48e-05	0.00112	CbGpPWpGaD
Erlotinib—JAK3—Immune System—TNFAIP3—systemic scleroderma	7.42e-05	0.00111	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	7.38e-05	0.0011	CbGpPWpGaD
Erlotinib—JAK3—Immune System—BLK—systemic scleroderma	7.33e-05	0.00109	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—MMP2—systemic scleroderma	7.3e-05	0.00109	CbGpPWpGaD
Erlotinib—Asthenia—Methotrexate—systemic scleroderma	7.27e-05	0.000314	CcSEcCtD
Erlotinib—MKNK1—Signaling Pathways—CSK—systemic scleroderma	7.22e-05	0.00108	CbGpPWpGaD
Erlotinib—Nausea—Prednisone—systemic scleroderma	7.2e-05	0.000311	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—systemic scleroderma	7.17e-05	0.000309	CcSEcCtD
Erlotinib—EGFR—Direct p53 effectors—MMP2—systemic scleroderma	7.16e-05	0.00107	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TGFB1—systemic scleroderma	7.15e-05	0.00107	CbGpPWpGaD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	7.04e-05	0.00105	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	6.99e-05	0.00104	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD247—systemic scleroderma	6.96e-05	0.00104	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ITGAM—systemic scleroderma	6.96e-05	0.00104	CbGpPWpGaD
Erlotinib—Diarrhoea—Methotrexate—systemic scleroderma	6.94e-05	0.000299	CcSEcCtD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	6.83e-05	0.00102	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.8e-05	0.00102	CbGpPWpGaD
Erlotinib—Dizziness—Methotrexate—systemic scleroderma	6.7e-05	0.000289	CcSEcCtD
Erlotinib—ABL1—Cell Cycle—TGFB1—systemic scleroderma	6.69e-05	0.000999	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—IL1B—systemic scleroderma	6.55e-05	0.000977	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—TNFAIP3—systemic scleroderma	6.52e-05	0.000973	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—MMP9—systemic scleroderma	6.51e-05	0.000972	CbGpPWpGaD
Erlotinib—Vomiting—Methotrexate—systemic scleroderma	6.44e-05	0.000278	CcSEcCtD
Erlotinib—Rash—Methotrexate—systemic scleroderma	6.39e-05	0.000276	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—systemic scleroderma	6.39e-05	0.000275	CcSEcCtD
Erlotinib—Headache—Methotrexate—systemic scleroderma	6.35e-05	0.000274	CcSEcCtD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	6.34e-05	0.000947	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SMAD7—systemic scleroderma	6.3e-05	0.000941	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	6.29e-05	0.000939	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—MMP9—systemic scleroderma	6.17e-05	0.000922	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CSK—systemic scleroderma	6.08e-05	0.000907	CbGpPWpGaD
Erlotinib—Nausea—Methotrexate—systemic scleroderma	6.02e-05	0.00026	CcSEcCtD
Erlotinib—JAK3—Immune System—CTLA4—systemic scleroderma	6e-05	0.000896	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IL1B—systemic scleroderma	6e-05	0.000896	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—RHOB—systemic scleroderma	5.98e-05	0.000893	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	5.97e-05	0.000891	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ITGAM—systemic scleroderma	5.95e-05	0.000888	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD247—systemic scleroderma	5.95e-05	0.000888	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD247—systemic scleroderma	5.71e-05	0.000853	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—EDN1—systemic scleroderma	5.69e-05	0.00085	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HSPG2—systemic scleroderma	5.64e-05	0.000842	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	5.6e-05	0.000837	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—TNFAIP3—systemic scleroderma	5.57e-05	0.000832	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—NOS3—systemic scleroderma	5.49e-05	0.000819	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—MMP9—systemic scleroderma	5.49e-05	0.000819	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CSK—systemic scleroderma	5.45e-05	0.000813	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—TGFB1—systemic scleroderma	5.36e-05	0.000801	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—MMP9—systemic scleroderma	5.35e-05	0.000799	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—BLK—systemic scleroderma	5.29e-05	0.000789	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EDN1—systemic scleroderma	5.17e-05	0.000772	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.15e-05	0.000769	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TGFB1—systemic scleroderma	5.09e-05	0.00076	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HLA-DQB1—systemic scleroderma	4.94e-05	0.000738	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—IL1B—systemic scleroderma	4.94e-05	0.000737	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RHOB—systemic scleroderma	4.88e-05	0.000728	CbGpPWpGaD
Erlotinib—EGFR—Disease—SMAD7—systemic scleroderma	4.83e-05	0.000721	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	4.77e-05	0.000712	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SELP—systemic scleroderma	4.76e-05	0.000711	CbGpPWpGaD
Erlotinib—UGT1A1—NRF2 pathway—TGFB1—systemic scleroderma	4.72e-05	0.000705	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL1A—systemic scleroderma	4.7e-05	0.000701	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD40LG—systemic scleroderma	4.67e-05	0.000697	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HSPG2—systemic scleroderma	4.6e-05	0.000686	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	4.56e-05	0.00068	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—TGFB1—systemic scleroderma	4.52e-05	0.000675	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—RHOB—systemic scleroderma	4.45e-05	0.000664	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CSK—systemic scleroderma	4.44e-05	0.000663	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—RHOB—systemic scleroderma	4.43e-05	0.000661	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFBI—systemic scleroderma	4.42e-05	0.00066	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	4.36e-05	0.00065	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CTLA4—systemic scleroderma	4.33e-05	0.000646	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CSK—systemic scleroderma	4.31e-05	0.000644	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—MMP2—systemic scleroderma	4.28e-05	0.00064	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IRF5—systemic scleroderma	4.24e-05	0.000634	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.19e-05	0.000625	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IRF8—systemic scleroderma	4.05e-05	0.000605	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD247—systemic scleroderma	4.05e-05	0.000605	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ITGAM—systemic scleroderma	4.05e-05	0.000605	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.05e-05	0.000605	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EDN1—systemic scleroderma	4.05e-05	0.000605	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—CSK—systemic scleroderma	4.05e-05	0.000605	CbGpPWpGaD
Erlotinib—ALB—Platelet degranulation—TGFB1—systemic scleroderma	4e-05	0.000597	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—MMP1—systemic scleroderma	3.88e-05	0.000579	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.84e-05	0.000573	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TGFB1—systemic scleroderma	3.83e-05	0.000573	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.82e-05	0.00057	CbGpPWpGaD
Erlotinib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	3.81e-05	0.000569	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—ITGAM—systemic scleroderma	3.81e-05	0.000568	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TNFAIP3—systemic scleroderma	3.8e-05	0.000567	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BLK—systemic scleroderma	3.75e-05	0.00056	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CSK—systemic scleroderma	3.69e-05	0.00055	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP2—systemic scleroderma	3.66e-05	0.000547	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TGFB1—systemic scleroderma	3.63e-05	0.000542	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRF5—systemic scleroderma	3.63e-05	0.000541	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.57e-05	0.000532	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.54e-05	0.000529	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CCL2—systemic scleroderma	3.53e-05	0.000528	CbGpPWpGaD
Erlotinib—EGFR—Disease—HSPG2—systemic scleroderma	3.52e-05	0.000526	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NOS3—systemic scleroderma	3.52e-05	0.000526	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRF8—systemic scleroderma	3.47e-05	0.000517	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD247—systemic scleroderma	3.47e-05	0.000517	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ITGAM—systemic scleroderma	3.47e-05	0.000517	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.46e-05	0.000517	CbGpPWpGaD
Erlotinib—EGFR—Disease—CSK—systemic scleroderma	3.4e-05	0.000508	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMAD7—systemic scleroderma	3.38e-05	0.000505	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD40LG—systemic scleroderma	3.37e-05	0.000503	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—HSPG2—systemic scleroderma	3.25e-05	0.000485	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TNFAIP3—systemic scleroderma	3.24e-05	0.000484	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—MMP9—systemic scleroderma	3.22e-05	0.000481	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BLK—systemic scleroderma	3.21e-05	0.000479	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD247—systemic scleroderma	3.2e-05	0.000478	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.17e-05	0.000474	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTLA4—systemic scleroderma	3.07e-05	0.000459	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	3.06e-05	0.000456	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EDN1—systemic scleroderma	3.05e-05	0.000456	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—HSPG2—systemic scleroderma	3.03e-05	0.000452	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.91e-05	0.000434	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.89e-05	0.000432	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NOS3—systemic scleroderma	2.81e-05	0.000419	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCL2—systemic scleroderma	2.77e-05	0.000413	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	2.75e-05	0.000411	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP9—systemic scleroderma	2.75e-05	0.000411	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.67e-05	0.000399	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTLA4—systemic scleroderma	2.63e-05	0.000392	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RHOB—systemic scleroderma	2.62e-05	0.000391	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP2—systemic scleroderma	2.61e-05	0.00039	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	2.53e-05	0.000378	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	2.49e-05	0.000372	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NOS3—systemic scleroderma	2.47e-05	0.000368	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HSPG2—systemic scleroderma	2.47e-05	0.000368	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CTGF—systemic scleroderma	2.46e-05	0.000367	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL1B—systemic scleroderma	2.45e-05	0.000366	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1A—systemic scleroderma	2.4e-05	0.000359	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD40LG—systemic scleroderma	2.39e-05	0.000357	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CSK—systemic scleroderma	2.38e-05	0.000356	CbGpPWpGaD
Erlotinib—MKNK1—Disease—TGFB1—systemic scleroderma	2.33e-05	0.000348	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	2.3e-05	0.000343	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CTGF—systemic scleroderma	2.29e-05	0.000343	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—EDN1—systemic scleroderma	2.26e-05	0.000338	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DQB1—systemic scleroderma	2.16e-05	0.000323	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CTGF—systemic scleroderma	2.09e-05	0.000312	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCL2—systemic scleroderma	2.09e-05	0.000312	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1A—systemic scleroderma	2.05e-05	0.000307	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD40LG—systemic scleroderma	2.04e-05	0.000305	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.02e-05	0.000302	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—systemic scleroderma	1.98e-05	0.000296	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	1.97e-05	0.000295	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—systemic scleroderma	1.96e-05	0.000293	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MMP1—systemic scleroderma	1.91e-05	0.000285	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	1.89e-05	0.000283	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HSPG2—systemic scleroderma	1.86e-05	0.000278	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOS3—systemic scleroderma	1.86e-05	0.000278	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	1.86e-05	0.000277	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.77e-05	0.000265	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.75e-05	0.000261	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.71e-05	0.000255	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	1.7e-05	0.000254	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HSPG2—systemic scleroderma	1.7e-05	0.000254	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TGFB1—systemic scleroderma	1.63e-05	0.000244	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TGFB1—systemic scleroderma	1.62e-05	0.000242	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL2—systemic scleroderma	1.55e-05	0.000231	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	1.52e-05	0.000226	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	1.5e-05	0.000223	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—systemic scleroderma	1.49e-05	0.000223	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.49e-05	0.000222	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CTGF—systemic scleroderma	1.41e-05	0.000211	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.4e-05	0.00021	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS3—systemic scleroderma	1.38e-05	0.000206	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EDN1—systemic scleroderma	1.34e-05	0.000199	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.3e-05	0.000193	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CTGF—systemic scleroderma	1.29e-05	0.000192	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—systemic scleroderma	1.25e-05	0.000187	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFB1—systemic scleroderma	1.23e-05	0.000184	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	1.22e-05	0.000182	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.19e-05	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS3—systemic scleroderma	1.16e-05	0.000174	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CTGF—systemic scleroderma	1.13e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—systemic scleroderma	1.07e-05	0.00016	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NOS3—systemic scleroderma	1.07e-05	0.00016	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.06e-05	0.000159	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	1e-05	0.00015	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NOS3—systemic scleroderma	9.99e-06	0.000149	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	9.18e-06	0.000137	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—systemic scleroderma	9.14e-06	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—systemic scleroderma	9.13e-06	0.000136	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—systemic scleroderma	9.09e-06	0.000136	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CTGF—systemic scleroderma	9.01e-06	0.000135	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—systemic scleroderma	8.14e-06	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—systemic scleroderma	7.69e-06	0.000115	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	6.95e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—systemic scleroderma	6.53e-06	9.75e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	6.51e-06	9.72e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—systemic scleroderma	6.15e-06	9.18e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—systemic scleroderma	5.64e-06	8.42e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—systemic scleroderma	5.61e-06	8.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—systemic scleroderma	5.38e-06	8.04e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—systemic scleroderma	4.91e-06	7.34e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—systemic scleroderma	4.63e-06	6.91e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—systemic scleroderma	3.92e-06	5.86e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.03e-06	4.52e-05	CbGpPWpGaD
